The number of coronavirus positive patients in India continues to increase alarmingly and is close to 4 lakhs. In this scenario, the antiviral drug developed by Glenmark Pharmaceuticals to treat coronavirus patients has received approval by the government. The name of the antiviral drug is Favipiravir which will be sold under the brand name Fabiflu. The Central Drugs Standard Control Organisation gave its approval on 19th June to Glenmark to manufacture and market Fabiflu in the country.
Fabiflu can be given to patients suffering from mild symptoms of corona infection and can be bought only on a doctor’s prescription. Glenmark has claimed that this drug has shown good results with patients suffering from mild coronavirus infection. The company expects the drug to ease the burden created by the massive influx of coronavirus patients on the doctors and other health workers.
As per Glenn Saldanha, the Chairman and Managing Director of Glenmark Pharmaceuticals, Febiflu gave good results with patients suffering mild symptoms of coronavirus infection during clinical trials. The drug is a convenient treatment option because it simply needs to be ingested orally by the patients. The company will fully cooperate with the government and the medical community to ensure that the drug is easily available for coronavirus patients in the country.